Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 2
2023 5
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean mambro v (8 results)?
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM; CHAPAS-4 Trial Team. Musiime V, et al. Among authors: mumbiro v. N Engl J Med. 2025 May 15;392(19):1917-1932. doi: 10.1056/NEJMoa2404597. N Engl J Med. 2025. PMID: 40367375 Free PMC article. Clinical Trial.
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa.
Katongole F, Arumugam T, Jennings A, Mutata C, Ssebunya P, Wamboi C, Green A, Bwakura-Dangarembizi M, Kityo C, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Mugerwa H, Walker S, Apoto N, Thomason MJ, Ford D, Pett SL, Kekitiinwa AR; BREATHER Plus trial team. Katongole F, et al. Contemp Clin Trials. 2025 Aug;155:107963. doi: 10.1016/j.cct.2025.107963. Epub 2025 May 29. Contemp Clin Trials. 2025. PMID: 40449658 Free PMC article.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial.
Bevers LAH, Waalewijn H, Szubert AJ, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Burger DM, Gibb DM, Colbers A. Bevers LAH, et al. Among authors: mumbiro v. Clin Infect Dis. 2023 Nov 11;77(9):1312-1317. doi: 10.1093/cid/ciad346. Clin Infect Dis. 2023. PMID: 37280040 Free PMC article. Clinical Trial.
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia.
Chabala C, Jacobs TG, Moraleda C, Ndaferankhande JM, Mumbiro V, Passanduca A, Namuziya N, Nalwanga D, Musiime V, Ballesteros A, Domínguez-Rodríguez S, Chitsamatanga M, Cassia U, Nduna B, Bramugy J, Sacarlal J, Madrid L, Nathoo KJ, Colbers A, Burger DM, Mulenga V, Buck WC, Mujuru HA, Te Brake LHM, Rojo P, Tagarro A, Aarnoutse RE; EMPIRICAL clinical trial group. Chabala C, et al. Among authors: mumbiro v. J Pediatric Infect Dis Soc. 2023 Nov 30;12(11):581-585. doi: 10.1093/jpids/piad088. J Pediatric Infect Dis Soc. 2023. PMID: 37843384 Free PMC article.
Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
Jacobs TG, Mumbiro V, Chitsamatanga M, Namuziya N, Passanduca A, Domínguez-Rodríguez S, Tagarro A, Nathoo KJ, Nduna B, Ballesteros A, Madrid L, Mujuru HA, Chabala C, Buck WC, Rojo P, Burger DM, Moraleda C, Colbers A; EMPIRICAL Clinical Trial Group; EMPIRICAL Clinical Trial Group. Jacobs TG, et al. Among authors: mumbiro v. J Acquir Immune Defic Syndr. 2023 May 1;93(1):42-46. doi: 10.1097/QAI.0000000000003168. Epub 2023 Apr 1. J Acquir Immune Defic Syndr. 2023. PMID: 36724434 Free PMC article.
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Waalewijn H, Szubert AJ, Wasmann RE, Wiesner L, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Monkiewicz LN, Griffiths AL, Bamford A, Doerholt K, Denti P, Burger DM, Gibb DM, McIlleron HM, Colbers A; Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens (CHAPAS-4) Trial Team. Waalewijn H, et al. Among authors: mumbiro v. Clin Infect Dis. 2023 Sep 18;77(6):875-882. doi: 10.1093/cid/ciad267. Clin Infect Dis. 2023. PMID: 37315296 Free PMC article. Clinical Trial.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Among authors: mumbiro v. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.
Jacobs TG, Mumbiro V, Cassia U, Zimba K, Nalwanga D, Ballesteros A, Domínguez-Rodríguez S, Tagarro A, Madrid L, Mutata C, Chitsamatanga M, Bwakura-Dangarembizi M, Passanduca A, Buck WC, Nduna B, Chabala C, Najjingo E, Musiime V, Moraleda C, Colbers A, Mujuru HA, Rojo P, Burger DM; EMPIRICAL Clinical Trial Group. Jacobs TG, et al. Among authors: mumbiro v. Clin Infect Dis. 2024 Mar 20;78(3):702-710. doi: 10.1093/cid/ciad656. Clin Infect Dis. 2024. PMID: 37882611 Free PMC article. Clinical Trial.
14 results